← Back to screener

Tyra Biosciences, Inc. TYRA

Rank #2180 · Nasdaq · $1.3B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
30.3
P/E
-14.5
P/B
6.13
ROE
-42.3%
Op. Margin
–%
Debt Ratio
10%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -14.5x, P/B 6.13x. Ranks in the top 76% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -42.3%. Ranks in the top 87% of the universe.

Safety ★★★★★
Excellent

Debt ratio 10%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2021–$-0.0B$-0.0B$-0.0B–-42
2022–$-0.0B$-0.0B$-0.0B–-36
2023–$-0.1B$-0.1B$0.3B–3
2024–$-0.1B$-0.1B$0.3B–8
2025–$-0.1B$-0.1B$0.2B–10

← See the full screener